rs828903 — MTHFD2

MTHFD2 — The Embryonic Folate Engine, Reawakened in Cancer

MTHFD2 (methylenetetrahydrofolate dehydrogenase 2) is the mitochondrial isoform of the folate-processing enzyme family. While MTHFD1 handles the same reactions in the cytoplasm, MTHFD2 operates in the mitochondrial matrix¹¹ mitochondrial matrix
The innermost compartment of the mitochondrion, where MTHFD2 oxidizes 5,10-methylene-THF to produce one-carbon units exported to the cytoplasm, converting 5,10-methyleneTHF to 10-formylTHF and feeding one-carbon units into the purine synthesis and methylation cycles. The gene has an unusual expression pattern: it is highly expressed during embryonic development, nearly silenced in most adult tissues, and then re-expressed at high levels in the vast majority of human cancers — earning it the label of a "developmental gene hijacked by cancer."

The rs828903 variant (A>G, intronic, chr2:74,209,593) sits within MTHFD2's coding sequence at the intron 6 splice region (c.563-348A>G). It does not alter the protein directly but may influence pre-mRNA splicing efficiency or intron retention patterns, potentially modulating MTHFD2 expression levels. The G allele has been studied in the context of folate pathway function, neural tube defect risk, and folate receptor autoantibody production.

The Mechanism

MTHFD2 catalyzes two sequential reactions in the mitochondria: the NAD(P)+- dependent oxidation of 5,10-methyleneTHF to 5,10-methenylTHF (dehydrogenase activity), followed by hydrolysis to 10-formylTHF (cyclohydrolase activity). The 10-formylTHF produced is the primary mitochondrial one-carbon donor, used to formylate mitochondrial methionyl-tRNA²² formylate mitochondrial methionyl-tRNA
Formylation of the initiator met-tRNA is required to start mitochondrial protein translation; MTHFD2 is therefore essential for mitochondrial ribosome function and to export one-carbon units to the cytoplasm for purine synthesis and methylation reactions.

The intronic rs828903 G allele may subtly alter splicing of MTHFD2 pre-mRNA. When MTHFD2 activity is reduced, mitochondrial one-carbon export to the cytoplasm decreases, constraining de novo purine synthesis and potentially reducing the folate available for homocysteine remethylation. Downstream consequences include elevated homocysteine and impaired rapid-cell-division processes — exactly the conditions that compromise early embryonic development and neural tube closure.

A separate mechanism connects MTHFD2 to the immune system: elevated MTHFD2 activity in endothelial cells under oxidized phospholipid stress³³ oxidized phospholipid stress
Oxidized phospholipids accumulate in atherosclerotic plaques and signal endothelial activation; MTHFD2 re-wires amino acid metabolism in response drives serine-glycine metabolism and nucleotide release, linking MTHFD2 function to cardiovascular inflammation.

The Evidence

Shaw et al. (2009)⁴⁴ Shaw et al. (2009)
Shaw GM et al. 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med Genet, 2009 genotyped 118 SNPs across folate pathway genes in 259 spina bifida cases, 214 conotruncal heart defect cases, and 359 controls from a California population registry. MTHFD2 variants including rs828903 showed protective odds ratios of approximately 0.6 (95% CI: 0.4–0.9) for spina bifida — an unexpected direction suggesting that the variant allele may alter folate flux in ways that reduce rather than increase neural tube defect risk in this study population. The authors noted widespread linkage disequilibrium among MTHFD2 SNPs, making independent effect estimation challenging.

Dong et al. (2018)⁵⁵ Dong et al. (2018)
Dong Y et al. Gene variants in the folate pathway are associated with increased levels of folate receptor autoantibodies. Birth Defects Res, 2018 found in 302 pregnant Chinese women that the rs828903 GG genotype was associated with significantly elevated folate receptor IgM autoantibody levels (β = 0.60, 95% CI 0.10–1.10). Folate receptor (FR) autoantibodies block folate uptake into cells⁶⁶ block folate uptake into cells
FR autoantibodies bind the folate receptor and sterically obstruct folate binding, reducing cellular folate uptake even when dietary folate is adequate and have been proposed as a mechanism for folate-related embryonic risk that operates independently of dietary folate intake. A person with the GG genotype and elevated FR autoantibodies may have functional folate insufficiency despite normal serum folate.

Hitzel et al. (2018)⁷⁷ Hitzel et al. (2018)
Hitzel J et al. Oxidized phospholipids regulate amino acid metabolism through MTHFD2. Nat Commun, 2018 showed that MTHFD2 controls serine-glycine-purine metabolism in endothelial cells in response to atherogenic oxidized phospholipids, and that SNPs within this MTHFD2-controlled metabolic cluster associate with coronary artery disease — adding a cardiovascular dimension to MTHFD2 genetic variation.

From a cancer perspective, Ramos et al. (2024)⁸⁸ Ramos et al. (2024)
Ramos L et al. Targeting MTHFD2 to exploit cancer-specific metabolism and the DNA damage response. Cancer Res, 2024 review MTHFD2 as re-expressed across numerous cancer types, correlating with poorer survival and representing an emerging therapeutic target. The cancer re-expression pattern reflects MTHFD2's embryonic developmental role — both cancer cells and embryonic cells require maximal one-carbon output for rapid division.

Practical Actions

For individuals with the GG genotype, the main concern is functional folate availability: the combination of potential MTHFD2 splicing effects and the risk of elevated folate receptor autoantibodies may reduce effective folate delivery even when dietary intake is adequate. Methylfolate supplementation and monitoring of functional folate status are the primary actions.

The variant also intersects with immune function via MTHFD2's role in T cell metabolism — MTHFD2 activity shapes the balance between inflammatory effector T cells and regulatory T cells, suggesting a connection between MTHFD2 function and autoimmune risk.

Interactions

MTHFD2 and MTHFD1 (rs2236224 / R653Q) catalyze the same reactions in different compartments — mitochondria vs cytoplasm — but supply the same cytoplasmic one-carbon pool. Carriers of MTHFD2 intronic variants alongside MTHFD1 R653Q may face compounded reduction in cytoplasmic one-carbon availability, amplifying the demand on the folate cycle. MTHFR C677T (rs1801133) further constrains this pathway by reducing conversion of folate to methylfolate.

Folate receptor autoantibodies associated with the GG genotype interact with dietary folate intake: the autoantibody-related block in folate uptake is most consequential when dietary folate is marginal. Higher methylfolate intake can partially overcome receptor-level blockade by saturating available receptors.